{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:43:12Z","timestamp":1790602992726,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"MOST","award":["MOST 108-2221-E-002-163-, MOST 109-2221-E-002 -083"],"award-info":[{"award-number":["MOST 108-2221-E-002-163-, MOST 109-2221-E-002 -083"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s00125-022-05772-9","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T19:02:31Z","timestamp":1660071751000},"page":"2032-2043","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Major adverse cardiovascular and limb events in people with diabetes treated with GLP-1 receptor agonists vs SGLT2 inhibitors"],"prefix":"10.1007","volume":"65","author":[{"given":"Donna Shu-Han","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Li","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Yun","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Wei","family":"Lien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Kuang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Jone","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,9]]},"reference":[{"key":"5772_CR1","doi-asserted-by":"publisher","unstructured":"Fox CS, Golden SH, Anderson C et al (2015) Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: A scientific statement from the American Heart Association and the American Diabetes Association. Circulation 132:691\u2013718. https:\/\/doi.org\/10.1161\/CIR.0000000000000230","DOI":"10.1161\/CIR.0000000000000230"},{"key":"5772_CR2","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/5584_2020_514","volume":"1307","author":"F Maranta","year":"2021","unstructured":"Maranta F, Cianfanelli L, Cianflone D (2021) Glycaemic Control and Vascular Complications in Diabetes Mellitus Type 2. Adv Exp Med Biol 1307:129\u2013152. https:\/\/doi.org\/10.1007\/5584_2020_514","journal-title":"Adv Exp Med Biol"},{"key":"5772_CR3","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1016\/j.jacc.2020.02.056","volume":"75","author":"T Wilcox","year":"2020","unstructured":"Wilcox T, De Block C, Schwartzbard AZ, Newman JD (2020) Diabetic agents, from metformin to SGLT2 inhibitors and GLP1 receptor agonists: JACC Focus Seminar. J Am Coll Cardiol 75:1956\u20131974. https:\/\/doi.org\/10.1016\/j.jacc.2020.02.056","journal-title":"J Am Coll Cardiol"},{"key":"5772_CR4","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jacc.2020.05.048","volume":"76","author":"LD Colantonio","year":"2020","unstructured":"Colantonio LD, Hubbard D, Monda KL et al (2020) Atherosclerotic risk and statin use among patients with peripheral artery disease. J Am Coll Cardiol 76:251\u2013264. https:\/\/doi.org\/10.1016\/j.jacc.2020.05.048","journal-title":"J Am Coll Cardiol"},{"key":"5772_CR5","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1161\/CIRCRESAHA.116.303849","volume":"116","author":"MH Criqui","year":"2015","unstructured":"Criqui MH, Aboyans V (2015) Epidemiology of peripheral artery disease. Circ Res 116:1509\u20131526. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.303849","journal-title":"Circ Res"},{"key":"5772_CR6","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311\u2013322. https:\/\/doi.org\/10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"key":"5772_CR7","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834\u20131844. https:\/\/doi.org\/10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"5772_CR8","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"5772_CR9","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S et al (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392:1519\u20131529. https:\/\/doi.org\/10.1016\/S0140-6736(18)32261-X","journal-title":"Lancet"},{"key":"5772_CR10","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644\u2013657. https:\/\/doi.org\/10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"key":"5772_CR11","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1161\/CIRCULATIONAHA.119.044775","volume":"142","author":"MP Bonaca","year":"2020","unstructured":"Bonaca MP, Wiviott SD, Zelniker TA et al (2020) Dapagliflozin and cardiac, kidney, and limb outcomes in patients with and without peripheral artery disease in DECLARE-TIMI 58. Circulation 142:734\u2013747. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044775","journal-title":"Circulation"},{"key":"5772_CR12","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"5772_CR13","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S et al (2020) Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med 383:1425\u20131435. https:\/\/doi.org\/10.1056\/NEJMoa2004967","journal-title":"N Engl J Med"},{"key":"5772_CR14","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.2337\/dc17-1551","volume":"41","author":"SE Inzucchi","year":"2018","unstructured":"Inzucchi SE, Iliev H, Pfarr E, Zinman B (2018) Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME Trial. Diabetes Care 41:e4\u2013e5. https:\/\/doi.org\/10.2337\/dc17-1551","journal-title":"Diabetes Care"},{"issue":"12","key":"5772_CR15","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1111\/dom.14159","volume":"22","author":"CY Huang","year":"2020","unstructured":"Huang CY, Lee JK (2020) Sodium-glucose co-transporter-2 inhibitors and major adverse limb events: A trial-level meta-analysis including 51\u2009713 individuals. Diabetes Obes Metab 22(12):2348\u20132355. https:\/\/doi.org\/10.1111\/dom.14159","journal-title":"Diabetes Obes Metab"},{"key":"5772_CR16","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1210\/clinem\/dgab274","volume":"106","author":"DS-H Lin","year":"2021","unstructured":"Lin DS-H, Lee J-K, Chen W-J (2021) Clinical adverse events associated with sodium-glucose cotransporter 2 inhibitors: a meta-analysis involving 10 randomized clinical trials and 71 553 individuals. J Clin Endocrinol Metab 106:2133\u20132145. https:\/\/doi.org\/10.1210\/clinem\/dgab274","journal-title":"J Clin Endocrinol Metab"},{"key":"5772_CR17","doi-asserted-by":"publisher","first-page":"k4365","DOI":"10.1136\/bmj.k4365","volume":"363","author":"P Ueda","year":"2018","unstructured":"Ueda P, Svanstr\u00f6m H, Melbye M et al (2018) Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ 363:k4365. https:\/\/doi.org\/10.1136\/bmj.k4365","journal-title":"BMJ"},{"key":"5772_CR18","doi-asserted-by":"publisher","first-page":"826","DOI":"10.2337\/dc20-1464","volume":"44","author":"E Patorno","year":"2021","unstructured":"Patorno E, Pawar A, Bessette LG et al (2021) Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists in older adults. Diabetes Care 44:826\u2013835. https:\/\/doi.org\/10.2337\/dc20-1464","journal-title":"Diabetes Care"},{"key":"5772_CR19","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.2337\/dc18-1094","volume":"41","author":"K Dhatariya","year":"2018","unstructured":"Dhatariya K, Bain SC, Buse JB et al (2018) The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: results from the LEADER Trial. Diabetes Care 41:2229\u20132235. https:\/\/doi.org\/10.2337\/dc18-1094","journal-title":"Diabetes Care"},{"key":"5772_CR20","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/CLEP.S196293","volume":"11","author":"C-Y Hsieh","year":"2019","unstructured":"Hsieh C-Y, Su C-C, Shao S-C et al (2019) Taiwan\u2019s National Health Insurance Research Database: past and future. Clin Epidemiol 11:349\u2013358. https:\/\/doi.org\/10.2147\/CLEP.S196293","journal-title":"Clin Epidemiol"},{"key":"5772_CR21","doi-asserted-by":"publisher","first-page":"e2018062","DOI":"10.4178\/epih.e2018062","volume":"40","author":"L-Y Lin","year":"2018","unstructured":"Lin L-Y, Warren-Gash C, Smeeth L, Chen P-C (2018) Data resource profile: the National Health Insurance Research Database (NHIRD). Epidemiol Health 40:e2018062. https:\/\/doi.org\/10.4178\/epih.e2018062","journal-title":"Epidemiol Health"},{"key":"5772_CR22","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1001\/jamainternmed.2015.3540","volume":"175","author":"AW Hsing","year":"2015","unstructured":"Hsing AW, Ioannidis JPA (2015) Nationwide population science: lessons from the Taiwan National Health Insurance Research Database. JAMA Intern Med 175:1527\u20131529. https:\/\/doi.org\/10.1001\/jamainternmed.2015.3540","journal-title":"JAMA Intern Med"},{"key":"5772_CR23","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/pds.2087","volume":"20","author":"C-L Cheng","year":"2011","unstructured":"Cheng C-L, Kao Y-HY, Lin S-J, Lee C-H, Lai ML (2011) Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf 20:236\u2013242. https:\/\/doi.org\/10.1002\/pds.2087","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5772_CR24","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ijcard.2015.07.075","volume":"201","author":"C-L Cheng","year":"2015","unstructured":"Cheng C-L, Chien H-C, Lee C-H, Lin S-J, Yang Y-HK (2015) Validity of in-hospital mortality data among patients with acute myocardial infarction or stroke in National Health Insurance Research Database in Taiwan. Int J Cardiol 201:96\u2013101. https:\/\/doi.org\/10.1016\/j.ijcard.2015.07.075","journal-title":"Int J Cardiol"},{"key":"5772_CR25","doi-asserted-by":"publisher","first-page":"500","DOI":"10.2188\/jea.je20140076","volume":"24","author":"C-L Cheng","year":"2014","unstructured":"Cheng C-L, Lee C-H, Chen P-S, Li Y-H, Lin S-J, Yang Y-HK (2014) Validation of acute myocardial infarction cases in the National Health Insurance Research Database in Taiwan. J Epidemiol 24:500\u2013507. https:\/\/doi.org\/10.2188\/jea.je20140076","journal-title":"J Epidemiol"},{"key":"5772_CR26","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jfma.2013.09.009","volume":"114","author":"C-Y Hsieh","year":"2015","unstructured":"Hsieh C-Y, Chen C-H, Li C-Y, Lai M-L (2015) Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database. J Formos Med Assoc 114:254\u2013259. https:\/\/doi.org\/10.1016\/j.jfma.2013.09.009","journal-title":"J Formos Med Assoc"},{"key":"5772_CR27","doi-asserted-by":"publisher","first-page":"108136","DOI":"10.1016\/j.diabres.2020.108136","volume":"163","author":"S Miyashita","year":"2020","unstructured":"Miyashita S, Kuno T, Takagi H et al (2020) Risk of amputation associated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of five randomized controlled trials. Diabetes Res Clin Pract 163:108136. https:\/\/doi.org\/10.1016\/j.diabres.2020.108136","journal-title":"Diabetes Res Clin Pract"},{"key":"5772_CR28","doi-asserted-by":"publisher","first-page":"e0234065","DOI":"10.1371\/journal.pone.0234065","volume":"15","author":"J Heyward","year":"2020","unstructured":"Heyward J, Mansour O, Olson L, Singh S, Alexander GC (2020) Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: a systematic review and meta-analysis. PLoS ONE 15:e0234065. https:\/\/doi.org\/10.1371\/journal.pone.0234065","journal-title":"PLoS ONE"},{"key":"5772_CR29","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1007\/s00125-021-05497-1","volume":"64","author":"DS-H Lin","year":"2021","unstructured":"Lin DS-H, Lee J-K, Chen W-J (2021) Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors. Diabetologia 64:1949\u20131962. https:\/\/doi.org\/10.1007\/s00125-021-05497-1","journal-title":"Diabetologia"},{"key":"5772_CR30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1677\/JOE-08-0468","volume":"201","author":"H Liu","year":"2009","unstructured":"Liu H, Dear AE, Knudsen LB, Simpson RW (2009) A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J Endocrinol 201:59\u201366. https:\/\/doi.org\/10.1677\/JOE-08-0468","journal-title":"J Endocrinol"},{"key":"5772_CR31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1677\/JOE-07-0387","volume":"196","author":"H Liu","year":"2008","unstructured":"Liu H, Hu Y, Simpson RW, Dear AE (2008) Glucagon-like peptide-1 attenuates tumour necrosis factor-alpha-mediated induction of plasminogen [corrected] activator inhibitor-1 expression. J Endocrinol 196:57\u201365. https:\/\/doi.org\/10.1677\/JOE-07-0387","journal-title":"J Endocrinol"},{"key":"5772_CR32","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1177\/1479164113481817","volume":"10","author":"T Gaspari","year":"2013","unstructured":"Gaspari T, Welungoda I, Widdop RE, Simpson RW, Dear AE (2013) The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE-\/- mouse model. Diab Vasc Dis Res 10:353\u2013360. https:\/\/doi.org\/10.1177\/1479164113481817","journal-title":"Diab Vasc Dis Res"},{"key":"5772_CR33","doi-asserted-by":"publisher","first-page":"E1209","DOI":"10.1152\/ajpendo.00237.2004","volume":"287","author":"T Nystr\u00f6m","year":"2004","unstructured":"Nystr\u00f6m T, Gutniak MK, Zhang Q et al (2004) Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 287:E1209\u2013E1215. https:\/\/doi.org\/10.1152\/ajpendo.00237.2004","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"5772_CR34","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.2337\/db14-0976","volume":"64","author":"J Koska","year":"2015","unstructured":"Koska J, Sands M, Burciu C et al (2015) Exenatide protects against glucose- and lipid-induced endothelial dysfunction: evidence for direct vasodilation effect of GLP-1 receptor agonists in humans. Diabetes 64:2624\u20132635. https:\/\/doi.org\/10.2337\/db14-0976","journal-title":"Diabetes"},{"key":"5772_CR35","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12933-016-0480-8","volume":"15","author":"M Rizzo","year":"2016","unstructured":"Rizzo M, Rizvi AA, Patti AM et al (2016) Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. Cardiovasc Diabetol 15:162. https:\/\/doi.org\/10.1186\/s12933-016-0480-8","journal-title":"Cardiovasc Diabetol"},{"key":"5772_CR36","doi-asserted-by":"publisher","first-page":"109076","DOI":"10.1016\/j.diabres.2021.109076","volume":"180","author":"F-C Hsiao","year":"2021","unstructured":"Hsiao F-C, Lin C-P, Tung Y-C, Wu C-T, Chu P-H (2021) Major adverse limb events in type 2 diabetes patients receiving glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a retrospective multi-institutional study. Diabetes Res Clin Pract 180:109076. https:\/\/doi.org\/10.1016\/j.diabres.2021.109076","journal-title":"Diabetes Res Clin Pract"},{"key":"5772_CR37","doi-asserted-by":"publisher","first-page":"278","DOI":"10.7326\/M20-0864","volume":"173","author":"A Tsapas","year":"2020","unstructured":"Tsapas A, Avgerinos I, Karagiannis T et al (2020) Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis. Ann Intern Med 173:278\u2013286. https:\/\/doi.org\/10.7326\/M20-0864","journal-title":"Ann Intern Med"},{"issue":"12","key":"5772_CR38","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1007\/s00125-021-05529-w","volume":"64","author":"DS Lin","year":"2021","unstructured":"Lin DS, Lee JK, Hung CS, Chen WJ (2021) The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials. Diabetologia. 64(12):2676\u20132686. https:\/\/doi.org\/10.1007\/s00125-021-05529-w","journal-title":"Diabetologia."},{"key":"5772_CR39","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.avsg.2020.10.022","volume":"73","author":"MP Goldman","year":"2021","unstructured":"Goldman MP, Corriere MA, Craven T et al (2021) Evaluation of neuropathy, glycemic control, and revascularization as risk factors for future lower extremity amputation among diabetic patients. Ann Vasc Surg 73:254\u2013263. https:\/\/doi.org\/10.1016\/j.avsg.2020.10.022","journal-title":"Ann Vasc Surg"},{"key":"5772_CR40","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1056\/NEJMra1615439","volume":"376","author":"DG Armstrong","year":"2017","unstructured":"Armstrong DG, Boulton AJM, Bus SA (2017) Diabetic foot ulcers and their recurrence. N Engl J Med 376:2367\u20132375. https:\/\/doi.org\/10.1056\/NEJMra1615439","journal-title":"N Engl J Med"},{"key":"5772_CR41","first-page":"14","volume":"65","author":"S Bajaj","year":"2017","unstructured":"Bajaj S, Mahajan A, Grover S, Mahajan V, Goyal P, Gupta VK (2017) Peripheral vascular disease in patients with diabetic foot ulcers \u2013 an emerging trend: a prospective study from North India. J Assoc Physicians India 65:14\u201317","journal-title":"J Assoc Physicians India"},{"key":"5772_CR42","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/1389203721999201208195901","volume":"22","author":"K Mehta","year":"2021","unstructured":"Mehta K, Behl T, Kumar A, Uddin MS, Zengin G, Arora S (2021) Deciphering the neuroprotective role of glucagon-like peptide-1 agonists in diabetic neuropathy: current perspective and future directions. Curr Protein Pept Sci 22:4\u201318. https:\/\/doi.org\/10.2174\/1389203721999201208195901","journal-title":"Curr Protein Pept Sci"},{"key":"5772_CR43","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1016\/j.jacc.2018.04.019","volume":"71","author":"JJV McMurray","year":"2018","unstructured":"McMurray JJV (2018) Only trials tell the truth about treatment effects. J Am Coll Cardiol 71:2640\u20132642. https:\/\/doi.org\/10.1016\/j.jacc.2018.04.019","journal-title":"J Am Coll Cardiol"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-022-05772-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-022-05772-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-022-05772-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:01:48Z","timestamp":1691539308000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-022-05772-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,9]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["5772"],"URL":"https:\/\/doi.org\/10.1007\/s00125-022-05772-9","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,9]]},"assertion":[{"value":"4 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}